Abstract: The invention relates to a method for producing an active substance laminate, especially an oral active substance laminate (100), having at least one active-substance-containing layer (31), which is arranged on a substrate (20), wherein the method comprises the following steps: a) providing a substrate (20) having an upper side (21) and an underside (22); b) applying an active-substance-containing mass (24) in a gap (25) formed by a first rotating roller (26) and a second rotating roller (27); c) transporting the substrate (20) to the second roller (27) by means of a third rotating roller (28) in such a way that the active-substance-containing mass (24) is applied to the upper side (21) of the substrate (20) by the second roller (27) in the form of an active-substance-containing layer (31); d) transporting an intermediate laminate (30), formed by the substrate (20) and the active-substance-containing layer (31), to a drying device (40); and e) drying the intermediate laminate (30), especially the active-su
Type:
Application
Filed:
April 5, 2018
Publication date:
January 30, 2020
Inventors:
Michael HOFFMANN, Elvira KIRSTGEN, Ralf-lngo STEIN, Sandra WIEDERSBERG, Thomas STUMPER
Abstract: Enteric elastomers and related methods are generally provided. In some embodiments, the enteric elastomer is a polymer composite. Certain embodiments comprise a polymer composite in which hydrogen bonds within two carboxyl group-containing polymers cross-link the polymer networks into an elastic and pH-responsive polymer composite. Advantageously, this polymer composite has the capacity of being stable and elastic in an acidic environment such as that of the stomach but can be dissolved in a neutral pH environment such as that of the small and large intestines. In some embodiments, the polymer composites described herein comprise a mixture of two or more polymers with carboxyl functionality such that the two or more polymers form hydrogen bonds. In certain embodiments, the polymer composite has both enteric and elastic properties.
Type:
Application
Filed:
July 31, 2019
Publication date:
January 30, 2020
Applicants:
Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc., Tokitae LLC
Inventors:
Shiyi Zhang, Andrew Bellinger, Carlo Giovanni Traverso, Robert S. Langer, Dean Liang Glettig, Lowell L. Wood, JR., Philip A. Eckhoff
Abstract: A hydrogen generator electrically coupled to a cloud monitoring system comprises a hydrogen generating device, a monitoring device, a network device, and a controlling device. The monitoring device monitors the machine condition of the hydrogen generating device and generates a condition signal. The network device selectively transmits a machine information including the condition signal to the cloud monitoring system. The controlling device receives an operating parameter from the cloud monitoring system via the network device and controls the hydrogen generating device according to the operating parameter. The hydrogen generator monitoring system of the present invention collects the relevant data of the user using the hydrogen generator and tracks the health status of the user to perform big data analysis.
Abstract: A biopatch, a bioheater, a biosensor and a bioelectronic patch device are provided. The biopatch comprises a polymer film comprising a biopolymer and a drug loaded in the polymer film. The biopolymer may comprise one or more than one of a bioabsorbable polymer, a biodegradable polymer and a biocompatible polymer. The biopolymer may comprise oxidized starch. The drug may comprise a first drug chemically combined with the oxidized starch and a second drug physically combined with the oxidized starch. The bioheater comprises a heater comprising biometal. The biometal may comprise Mg or Fe. The heater can be controlled wirelessly by an alternating magnetic field.
Type:
Application
Filed:
December 7, 2016
Publication date:
January 30, 2020
Inventors:
Daehyeong KIM, Seunghong CHOI, Taeghwan HYEON, Jongha LEE, Hyerim CHO, Hyunseon SEO
Abstract: Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient's entire immune system. Methods include localized release of immunosuppressive (ISV) agents are contemplated in one embodiment. Methods also include localized application of immunosuppressive (ISV) regulatory T-cells (Tregs) and/or mesenchymal stomal cells in other embodiments. Hydrogel carrier materials are also described herein.
Abstract: Microspheres, compositions including the microspheres, and methods of using the microspheres are disclosed herein. The microspheres can be substantially spherical and can include a copolymer of a monomer (such as an acrylic monomer) and a cyclodextrin or a derivative thereof. The microspheres can also include a therapeutic agent, such as a platinum-based drug.
Abstract: Formulations are provided for the oral administration of avanafil, a Type V phosphodiesterase inhibitor (“PDE V inhibitor”), and analogs thereof. The formulations are orally disintegrating tablets (ODTs) that rapidly dissolve or disintegrate in the oral cavity. The tablets contain an absorption enhancing composition that increases the duodenal absorption of the active agent, following transfer from the low pH environment of the stomach to the more basic pH of the duodenum. Methods for administering the active agent using the dosage forms are provided. The invention also encompasses a method of selecting components and compositions to incorporate in the formulations which will facilitate increased absorption of the active agent in the duodenum and thus serve as “absorption enhancing compositions” herein. Also provided are methods for manufacturing orally disintegrating tablets to optimize the physical properties of the dosage forms, particularly hardness and disintegration time.
Abstract: Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are also provided.
Abstract: Drug delivery using bio-affecting drugs, particularly with shape changing drug delivery devices. Embodiments are included for depots for delivery of a therapeutic agent that change from an elongated state ex vivo to a coil in vivo where the agent is released.
Type:
Application
Filed:
August 6, 2019
Publication date:
January 30, 2020
Inventors:
Peter Jarrett, Michael J. McGrath, Timothy S. Jarrett, Rami El-Hayek, Andrew C. Vanslette, Courtney A. Rosales, Charles D. Blizzard, Amarpreet S. Sawhney
Abstract: A pharmaceutically acceptable oral dosage form for delivery of an agent to an intestinal site has one or more active agent regions having an active agent to be delivered to the intestinal site, one or more drying agent regions having at least one drying agent therein capable of drying an area about the intestinal site, the one or more drying agent regions being separate from the one or more active agent regions, and a protective coating at least partially covering a surface of the form. The dosage form has a fluid uptake capacity as measured for the entire dosage form when immersed in a fluid media according to a Dosage Form Fluid Uptake Assay of at least about 20 g fluid per dosage form.
Type:
Application
Filed:
February 3, 2017
Publication date:
January 30, 2020
Inventors:
Daniel BONNER, John JANTZ, Peter TRAN, Rachel SHAPIRO, Nicholas PILLA, Jules JACOB, Braden KUO, Colin Rober GARDNER, Padmaja SHIVANAND, Jacob BARLOW, Lisa Viana FERREIRA
Abstract: Provided are stem cell biomimetic microparticles comprised of at least one stem cell-derived paracrine polypeptide or growth factor embedded in a polymer core particle that further comprises an outer layer of at least one fragment of a cell membrane of a stem cell disposed on the core particle. The polymer core may be constituted of any biocompatible and biodegradable polymer or copolymer, or a combination thereof that allows the embedding of the paracrine factors and their prolonged release from the core. The core and hence the microparticles can be biodegradable, allowing eventual elimination from the recipient animal or human subject. The core particles are sized to allow both transport through blood vessels and extravasation from the blood vessels into the surrounding tissues. The core particle may further include at least one polypeptide or peptide growth factor to induce the generation and proliferation of a population of stem cells.
Abstract: Methods for intravesical administration of a therapeutic agent including application of a photoactive nanogel to the mucosal surfaces of the bladder and/or intravesical application of cell-penetrating peptides. Photoactive nanogels may be aggregated by exposure to ultraviolet light, either in vitro or in vivo, to provide controlled or extended release of a therapeutic agent, such as an antibiotic.
Type:
Application
Filed:
March 23, 2018
Publication date:
January 30, 2020
Inventors:
Devatha P. NAIR, Dmitri SIMBERG, Manju SARASWATHY
Abstract: Provided is a process for the production of nano- and/or microparticles containing a therapeutically active agent embedded in a polymer matrix or encapsulated by a polymer shell, and nano- and/or microparticles obtainable by the process, said process comprising the steps of: a) providing a solution of a polymer selected from polylactide, polyglycolide, and polyester copolymers comprising copolymerized units of lactic acid and/or glycolic acid in an organic solvent SI having limited water solubility: b) providing a solution or dispersion of a therapeutically active agent in as solvent or mixture of organic solvents S2 comprising at least 50 vol.
Abstract: The present invention aims to dramatically increase the effect of hepatic arterial chemoembolization by developing human serum albumin-based nanoparticles, which are bioproteins that effectively carry Adriamycin in place of Adriamycin, an anticancer agent used in hepatic arterial chemoembolization. The human serum albumin nanoparticles carrying the Adriamycin not only intensively infiltrate the drug effectively into the cells but also have a synergistic effect that can induce a long-term therapeutic effect by utilizing the effect of continuous drug release from the particles.
Type:
Application
Filed:
September 27, 2017
Publication date:
January 30, 2020
Applicants:
SOGANG UNIVERSITY RESEARCH FOUNDATION, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, IMGT CO,LTD.
Inventors:
Hyun Cheol KIM, Jin Wook CHUNG, Eun Ah JUNG
Abstract: Disclosed herein is a delivery platform for the preparation of versatile sol-gel/hydrogel based nano and micro particles that can be loaded with small molecules. The delivery platform is suitable for topical, transdermal, IV, IP and aerosol drug delivery. Also disclosed herein are methods of treatment using the aforementioned particles.
Type:
Application
Filed:
February 9, 2018
Publication date:
January 30, 2020
Inventors:
JOEL FRIEDMAN, ANDREW DRAGANSKI, ADAM FRIEDMAN, MAHANTESH NAVATI, PARIMALA NACHARAJU
Abstract: Disclosed herein are gelatin particles that have been crosslinked without using a crosslinking agent and are easily taken up by cells themselves, and a method for producing such gelatin particles. The gelatin particles are made of self-crosslinked gelatin and have a particle diameter of 0.010 ?m or more but 5.0 ?m or less. The gelatin particles can be produced by discharging droplets of a liquid containing melted gelatin into air in a heating tube or a drying chamber and drying the droplets to form the gelatin into particles under conditions where a difference between the temperature in the heating tube or the drying chamber and the temperature of the liquid is 235° C. or less and further by crosslinking the gelatin forming the particles.
Abstract: The present invention provides a liquid composition comprising a pharmaceutically active compound and an aqueous polymer dispersion, wherein said liquid composition forms a film upon drying under standard ambient temperature and pressure; a method for providing the same; and a container comprising said liquid composition.
Abstract: A transdermal patch is provided for use during oil delivery to a user's skin. The patch has a first foam member and a second foam member positioned adjacent the first foam member. An adhesive member is attached to the second foam member for securing the patch to a user's skin. A release liner covers and extends across the adhesive member. A gap can be formed between the first foam member and the second foam member and surrounds the first foam member. The first foam member has a thickness which is greater than a thickness of the second foam member.
Type:
Application
Filed:
March 21, 2019
Publication date:
January 30, 2020
Applicant:
Chemsultants International Inc.
Inventors:
Berryinne Decker, Keith Muny, Gary Avalon, Brian Buehner
Abstract: Provided herein are ketamine gel formulations, transdermal delivery devices comprising ketamine, methods of preparation and methods of using thereof. The transdermal delivery device can be a drug-in-reservoir (DIR) patch comprising ketamine, which typically includes a backing layer, a reservoir layer comprising a ketamine gel formulation, a rate-controlling membrane, an adhesive layer, and a release liner. The ketamine gel formulation generally includes one or more skin permeation enhancers. The transdermal delivery devices can be configured, for example, by adjusting the ketamine gel formulation and other release control mechanisms, to provide certain skin flux characteristics, and can be used for treating a variety of indications such as depression and/or pain.
Type:
Application
Filed:
April 19, 2018
Publication date:
January 30, 2020
Inventors:
Huadong TANG, Hock S. TAN, Michael MAYERSOHN
Abstract: A novel pharmaceutical composition is provided comprising beta-caryophyllene or a functionally equivalent derivative, analogue or pharmaceutically acceptable salt thereof in a base cream comprising triglycerides, phospholipid, water, wax, alcohol, with other minor constituents. The composition is useful to treat pain and/or inflammation, reduce fine lines and wrinkles, moisturize, and protect skin with anti-bacterial, anti-fungal and insect repelling properties.
Abstract: In embodiments, the invention includes treatment compositions for treatment of wounds and body dysfunction due to injury, aging, degeneration, obesity, or disease. It includes compositions and methods of administering the compositions. The compositions include cannabidiol and either human stem cells or stem cell products.
Abstract: Methods and compositions are described for use in encouraging angiogenesis and skin healing as may be utilized in wound treatment, as well as in encouragement of angiogenesis in disease. Compositions include an effective amount of a natural pimarane diterpenoid extract of Hymenocrater elegans, or a derivative, analogue, or homolog thereof. Compounds based upon this natural extract have been found to be highly effective in vascular formation and skin closure while exhibiting low toxicity.
Type:
Application
Filed:
September 23, 2019
Publication date:
January 30, 2020
Inventors:
EHSAN JABBARZADEH, SARA Eslambolchimoghadam
Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
Type:
Application
Filed:
October 7, 2019
Publication date:
January 30, 2020
Applicant:
ZYNERBA PHARMACEUTICALS, INC.
Inventors:
Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
Abstract: Methods for treating excess pigmentation, including treatment of post inflammatory hyperpigmentation (PIH), are disclosed. The disclosed methods comprise administration of a composition comprising bakuchiol substantially free of furanocoumarins to a mammal. Compositions comprising bakuchiol and methods for their preparation are also disclosed.
Type:
Application
Filed:
October 7, 2019
Publication date:
January 30, 2020
Applicant:
Unigen, Inc.
Inventors:
Mei Feng Hong, Qi Jia, Lidia Alfaro Brownell
Abstract: The present disclosure relates to a pharmaceutical composition for treating gallbladder disease containing a gallstone-dissolving agent, and more specifically, to a pharmaceutical composition for treating gallbladder disease containing a gallstone-dissolving agent which dissolves gallstone, a cause of the gallbladder disease, and thus has an excellent effect of alleviating or treating any one or more symptoms selected from the group consisting of asymptomatic cholelithiasis, biliary colic, cholecystitis, choledocholithiasis, and biliary pancreatitis.
Type:
Application
Filed:
September 19, 2017
Publication date:
January 30, 2020
Inventors:
Say June KIM, Kwan Young JEONG, Ok Hee KIM, Seok Jun JO, Min Jin YOO
Abstract: A method for rapidly improving cardiovascular function, reducing arterial stiffness and reversing calcification of a blood vessel in a mammal comprising administering to the mammal an effective amount of vitamin K for a period of less than 6 months. Also a method for increasing endothelial nitric oxide production in mammals comprising administering to the mammal an effective amount of vitamin K for a period of less than 6 months. The vitamin K can be administered together with additional substances such as vitamin D.
Abstract: The present invention relates to the use of an antiestrogen such as trans-clomiphene or an analogue or salt thereof, and/or an aromatase inhibitor to treat obesity and/or a symptom associated therewith.
Type:
Application
Filed:
September 25, 2017
Publication date:
January 30, 2020
Inventors:
Joseph S. Podolski, Jaye Thompson, Martin Sandel
Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating a mammal having an epileptic seizure disorder or being at risk for having an epileptic seizure disorder, comprising administering certain herein disclosed isolated fenfluramine enantiomers that are surprisingly effective as anti-epilepsy drugs (AEDs), despite having lower anti-seizure potency than fenfluramine racemate, by virtue of also being less cardiotoxic than fenfluramine racemate. Preferred embodiments contemplate treatment of Dravet syndrome; other preferred embodiments contemplate treatment of other epileptic seizure disorders.
Type:
Application
Filed:
July 26, 2019
Publication date:
January 30, 2020
Inventors:
Robin Paul Sherrington, Jean-Jacques Alexandre Cadieux, Parisa Karimi Tari, Jeffrey Paul Bechard
Abstract: This disclosure concerns the discovery of the use of fenoterol analogues for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analogue to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.
Type:
Application
Filed:
October 11, 2019
Publication date:
January 30, 2020
Applicant:
The United States of America, as represented by the Secretary, Department of Health and Human Servic
Inventors:
Irving W. Wainer, Michel Bernier, Rajib K. Paul
Abstract: The present invention relates to compounds and methods for increasing or agonizing Sigma 1 Receptors and its pathway for treating long QT syndrome (LQTS), and in particular Timothy Syndrome (TS), LQT8, LQT1, LQT2, and LQT6. Additionally, the invention relates to small molecule based therapies and combinations for treating Timothy Syndrome (TS), LQT8, LQT1, LQT2, LQT6 and related channelopathies.
Type:
Application
Filed:
October 4, 2019
Publication date:
January 30, 2020
Inventors:
Masayuki Yazawa, LouJin Song, Kumi Morikawa, Jose Quejada, Ramsey Bekdash
Abstract: Disclosed is a method of promoting wound healing with reduced scarring after glaucoma filtration surgery in a mammalian subject in need thereof, which involve the use of a HDAC inhibitor (HDACi), such as, but not limited to, suberoylanilide hydroxamic acid (SAHA).
Abstract: A pharmaceutical composition for topical administration includes a therapeutically safe and effective amount of a lidocaine salt, a therapeutically safe and effective amount of a tetracaine salt, distilled water, and hydroxyethyl cellulose.
Abstract: The disclosure herein relates to antipurinergic compounds and uses thereof. Specifically, the disclosure relates to the use of antipurinergic compounds to treat neurodevelopmental disorders. More specifically, the disclosure relates to the use of suramin for the treatment of autism spectral disorders (ASDs). More specifically, the present disclosure relates to non-intravenously administered suramin for the treatment of ASDs.
Abstract: The invention relates to compositions and uses thereof in methods for treating an inflammatory disease, disorder or condition in a subject, in particular an inflammatory disease, disorder or condition of the digestive tract such as inflammatory bowel disease (IBD) and/or colorectal cancer. The invention also relates to probiotic compositions and the use of the compositions for treating gastrointestinal disorders.
Type:
Application
Filed:
September 21, 2017
Publication date:
January 30, 2020
Inventors:
Benjamin BRADLEY, Edward GREEN, Daniela HEEG
Abstract: The invention relates to an agent for use in the prophylaxis or treatment of dyslipidemia, in particular for the treatment of excessive/elevated LDL levels, containing propionic acid or a physiologically acceptable propionic acid derivative.
Abstract: Described herein are compositions and methods for the increasing the quantity of lipids secreted from meibomian glands. Such compositions and methods are useful for the treatment of meibomian gland dysfunction and disorders resulting therefrom.
Abstract: The invention relates to compositions comprising abscisic acid, and/or salts, and derivatives thereof, and methods of using the same for improving the health, growth, and feed efficiency of livestock and fish as well as the quantity of meat produced in livestock in particular.
Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
Inventors:
Anke Stroyer, Carmen Lobback, Peter Serno, Philipp Rubenbauer, Kai Lovis, Heiko Schirmer, Danja Grossbach, Donald Bierer, Britta Olenik, Tia Jacobs, Julia Kusel
Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
Type:
Application
Filed:
October 7, 2019
Publication date:
January 30, 2020
Applicant:
United Therapeutics Corporation
Inventors:
Hitesh BATRA, Sudersan M. TULADHAR, Raju PENMASTA, David A. WALSH
Abstract: In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).
Type:
Application
Filed:
October 4, 2019
Publication date:
January 30, 2020
Applicant:
The Regents of the University of California
Abstract: The present invention relates to compositions and methods to increase nitric oxide production to: accelerate wound healing, reduce complications from surgery as well as accelerating the recovery period after surgery. The compositions comprise of l-arginine and l-citrulline in ratios and dosages which enable enhanced bioavailability. The method for using the composition for promoting surgery recovery and preparedness includes the step of administering the composition to a patient pre-procedure as well as post-procedure in accordance with a prescribed protocol. The compositions may be customized to include one or more additional agents that are effective for promoting nutritional health and/or treating a particular medical problem.
Abstract: Compositions containing at least four kinds of amino acids selected from the group consisting of serine, aspartic acid, glutamic acid, glycine, alanine and proline as active ingredients are useful for improving joint function and skin function and have high safety and permit continued ingestion or administration.
Abstract: The object of the present invention is to potentiate the photodynamic effect in ALA-PDT and ALA-PDD. The present invention provides a pharmaceutical related to a combination of ALAs and a dynamin inhibitor.
Abstract: Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including, in particular, an antimicrobial lipid component, such as a fatty acid ester, fatty ether, or alkoxide derivative thereof. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and/or a hydrophilic component. Such compositions provide effective topical antimicrobial activity and are accordingly useful in the treatment and/or prevention of conditions that are caused, or aggravated by, microorganisms (including viruses).
Type:
Application
Filed:
October 4, 2019
Publication date:
January 30, 2020
Inventors:
Matthew T. Scholz, Dianne L. Gibbs, John T. Capecchi, Jeffrey F. Andrews
Abstract: A formulation, including: (a) a first medicament, wherein the first medicament includes an isothiocyanate functional compound/surfactant; and (b) a second medicament, wherein the second medicament includes an antineoplastic agent, such as a cytotoxic antineoplastic agent and/or a targeted antineoplastic agent.
Abstract: Disclosed herein, in part, are pharmaceutical compositions comprising a MetAp-2 inhibitor and a pharmaceutically acceptable excipient. The pharmaceutical compositions are contemplated to be useful, for example in the treatment of obesity.
Abstract: The present invention relates to a combination therapy for tumours comprising the administration of an epoxytigliane compound and an immune checkpoint inhibitor. In particular embodiments, there is a method of treating a tumour and/or treating or preventing one or more bystander tumours with the therapy. Pharmaceutical compositions and kits containing epoxytigliane compounds and immune checkpoint inhibitors are also described.
Type:
Application
Filed:
March 23, 2018
Publication date:
January 30, 2020
Inventors:
Paul Warren Reddell, Jason Kingsley Cullen, Glen Mathew Boyle, Peter Gordon Parsons, Victoria Anne Gordon
Abstract: A method of treatment or prevention of fibrosis of human tissue or organ. The method includes administering a patient in need thereof a compound of formula (I).
Type:
Application
Filed:
September 30, 2019
Publication date:
January 30, 2020
Inventors:
Guifu DAI, Haiwei XU, Zhenzhen GUAN, Yake WANG, Di WU, Pengpeng SHEN, Ning SHANG, Fengjuan WU, Jin ZHAO, Xiaopei ZHANG
Abstract: The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.
Abstract: A method of treating a malignant disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a first liquid chromatography fraction of a Cannabis extract comprising at least 75% tetrahydrocannabinolic acid (THCA), and a therapeutically effective amount of a second liquid chromatography fraction of a Cannabis extract comprising at least 75% cannabigerolic acid (CBGA), wherein the first liquid chromatography fraction comprises Cannabis derived active ingredients other than the THCA, and the second liquid chromatography fraction comprises Cannabis derived active ingredients other than the CBGA, thereby treating the malignant disease in the subject.
Type:
Application
Filed:
March 5, 2018
Publication date:
January 30, 2020
Applicants:
The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization, Mor Research Applications Ltd.